Citadel Advisors’s Aridis Pharmaceuticals Inc. Common Stock ARDS Stock Holding History

Citadel Advisors’s Portfolio ARDS Stock Details ARDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-19,000	Closed	-$4.18K	–	15610
2023 Q2	$4.18K	Sell	19,000 -5,500	-22%	-$1.27K	﹤0.01%	13623
2023 Q1	$7.7K	Buy	+24,500	New	+$17.8K	﹤0.01%	13702
2022 Q4	–	Sell	-11,800	Closed	-$11K	–	15727
2022 Q3	$11K	Buy	11,800 +1,400	+13%	+$2.18K	﹤0.01%	12263
2022 Q2	$11K	Buy	+10,400	New	+$12.9K	﹤0.01%	12572

Other funds holding ARDS

Wealth Architects Mountain View, California $1.27B AUM 36.93% 1-Year Est. Return

Citadel Advisors's ARDS Position: Q4 2022 in Review

Citadel Advisors sold out of Aridis Pharmaceuticals Inc. Common Stock (ARDS) in Q4 2022, closing a stake of 54,386 shares — an estimated $51K sold.

Citadel Advisors first reported a position in ARDS in Q4 2021 and held it in 4 quarters. The position peaked at $51K in Q3 2022. 17 funds tracked by Wall St. Rank hold ARDS as of Q4 2022.

Citadel Advisors reported no remaining Aridis Pharmaceuticals Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Citadel Advisors sold 54,386 Aridis Pharmaceuticals Inc. Common Stock shares in Q4 2022, an estimated $51K.
Citadel Advisors first reported a position in Aridis Pharmaceuticals Inc. Common Stock in Q4 2021 and held it in 4 quarters.
Citadel Advisors's Aridis Pharmaceuticals Inc. Common Stock position peaked at $51K in Q3 2022.
17 funds tracked by Wall St. Rank held Aridis Pharmaceuticals Inc. Common Stock as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.